Capital Research Global Investors
IDYA icon

Capital Research Global Investors’s IDEAYA Biosciences IDYA Stock Holding History

Capital Research Global Investors’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199M Buy
5,344,701
+181,158
+4% +$5.55M 0.03% 235
2026
Q1 		$172M Sell
5,163,543
-116,132
-2% -$3.9M 0.03% 258
2025
Q4 		$183M Sell
5,279,675
-1,273,016
-19% -$40.6M 0.03% 234
2025
Q3 		$178M Hold
6,552,691
– – 0.03% 234
2025
Q2 		$138M Buy
6,552,691
+3,817,768
+140% +$73.2M 0.03% 262
2025
Q1 		$44.8M Buy
2,734,923
+169,026
+7% +$3.6M 0.01% 362
2024
Q4 		$65.9M Sell
2,565,897
-459
-0% -$13K 0.01% 337
2024
Q3 		$81.3M Buy
2,566,356
+401,805
+19% +$15.2M 0.02% 301
2024
Q2 		$76M Buy
2,164,551
+187,681
+9% +$7.43M 0.02% 299
2024
Q1 		$86.7M Hold
1,976,870
– – 0.02% 299
2023
Q4 		$70.3M Buy
1,976,870
+600,000
+44% +$17.9M 0.02% 302
2023
Q3 		$37.1M Buy
1,376,870
+653,068
+90% +$16.6M 0.01% 342
2023
Q2 		$17M Buy
+723,802
New +$14.9M ﹤0.01% 366

Other funds holding IDYA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GP
GSK plc London $602M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Capital Research Global Investors's IDYA Position: Q2 2026 in Review

Capital Research Global Investors increased its IDEAYA Biosciences (IDYA) stake by 3.5% in Q2 2026, buying an estimated $5.55M and bringing the position to 5,344,701 shares worth $199M. The position accounts for 0.03% of the portfolio, ranked #235.

Capital Research Global Investors first reported a position in IDYA in Q2 2023 and has held it in 13 quarters since. 193 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Capital Research Global Investors held 5,344,701 shares of IDEAYA Biosciences worth $199M as of Q2 2026.
  • Capital Research Global Investors bought 181,158 IDEAYA Biosciences shares in Q2 2026, an estimated $5.55M.
  • IDEAYA Biosciences made up 0.03% of Capital Research Global Investors's portfolio in Q2 2026, its #235 holding.
  • Capital Research Global Investors first reported a position in IDEAYA Biosciences in Q2 2023 and has held it in 13 quarters since.
  • 193 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.